BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 12750439)

  • 1. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
    Cunha-Reis D; Ribeiro JA; Sebastião AM
    Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for the involvement of VPAC1 and VPAC2 receptors in pressure-induced vasodilatation in rodents.
    Fizanne L; Sigaudo-Roussel D; Saumet JL; Fromy B
    J Physiol; 2004 Jan; 554(Pt 2):519-28. PubMed ID: 14578481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.
    Grant S; Lutz EM; McPhaden AR; Wadsworth RM
    J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
    J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production.
    Kojima M; Ito T; Oono T; Hisano T; Igarashi H; Arita Y; Kawabe K; Coy DH; Jensen RT; Nawata H
    Pancreas; 2005 Jan; 30(1):62-70. PubMed ID: 15632701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hexanoylation of a VPAC2 receptor-preferring ligand markedly increased its selectivity and potency.
    Langer I; Gregoire F; Nachtergael I; De Neef P; Vertongen P; Robberecht P
    Peptides; 2004 Feb; 25(2):275-8. PubMed ID: 15063009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
    St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
    Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic AMP-dependent protein kinase in Molt 4b lymphoblasts: identification by photoaffinity labeling and activation in intact cells by vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI).
    O'Dorisio MS; Wood CL; Wenger GD; Vassalo LM
    J Immunol; 1985 Jun; 134(6):4078-86. PubMed ID: 2985703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy.
    Dvoráková MC; Pfeil U; Kuncová J; Svíglerová J; Galvis G; Krasteva G; König P; Grau V; Slavíková J; Kummer W
    Cell Tissue Res; 2006 Mar; 323(3):383-93. PubMed ID: 16344947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of vasoactive intestinal peptide-elicited coronary vasodilation in the isolated perfused rat heart.
    Sawmiller DR; Ashtari M; Urueta H; Leschinsky M; Henning RJ
    Neuropeptides; 2006 Oct; 40(5):349-55. PubMed ID: 17030371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
    Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
    Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunocytochemical identification of VPAC1, VPAC2, and PAC1 receptors in normal and neoplastic human tissues with subtype-specific antibodies.
    Schulz S; Röcken C; Mawrin C; Weise W; Höllt V; Schulz S
    Clin Cancer Res; 2004 Dec; 10(24):8235-42. PubMed ID: 15623599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
    García-Fernández MO; Collado B; Bodega G; Cortés J; Ruíz-Villaespesa A; Carmena MJ; Prieto JC
    Gynecol Endocrinol; 2005 Jun; 20(6):327-33. PubMed ID: 16019382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vasoactive intestinal peptide (VIP) stimulates cortisol secretion from the H295 human adrenocortical tumour cell line via VPAC1 receptors.
    Nicol MR; Cobb VJ; Williams BC; Morley SD; Walker SW; Mason JI
    J Mol Endocrinol; 2004 Jun; 32(3):869-77. PubMed ID: 15171718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide stimulate interleukin-6 production in prostate cancer cells and prostatic epithelial cells.
    Nagakawa O; Junicho A; Akashi T; Koizumi K; Matsuda T; Fuse H; Saiki I
    Oncol Rep; 2005 Jun; 13(6):1217-21. PubMed ID: 15870945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary vascular effects of vasoactive intestinal peptide in the isolated perfused rat heart.
    Sawmiller DR; Henning RJ; Cuevas J; Dehaven WI; Vesely DL
    Neuropeptides; 2004 Oct; 38(5):289-97. PubMed ID: 15464194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VPAC1 (vasoactive intestinal peptide (VIP) receptor type 1) G protein-coupled receptor mediation of VIP enhancement of murine experimental colitis.
    Yadav M; Huang MC; Goetzl EJ
    Cell Immunol; 2011; 267(2):124-32. PubMed ID: 21295288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
    Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
    Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.